Full text is available at the source.
Abstract
A cohort of patients with obesity was treated with semaglutide or tirzepatide under Japan's GLP-1 receptor agonist therapy guidelines.
- Insurance reimbursement for GLP-1 receptor agonist therapy is contingent upon completing a 6-month lifestyle intervention.
- Treatment duration is limited to 68 weeks for semaglutide 2.4 mg and 72 weeks for tirzepatide.
- A mandated washout period follows the treatment phase.
- Pre-treatment weight change during the lifestyle phase may influence the response to the medication.
- On-treatment response and subsequent weight regain after cessation were evaluated in the real-world cohort.
Simplified